Table 1 Participant characteristics at baseline in 103 participants with severe COVID-19 randomized to treatment with convalescent plasma versus placebo.

From: Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)

 

CCP, n (%)

Placebo, n (%)

Total (%)

Total

52

51

103

Age group (years)

< 40

9 (17.3)

6 (11.8)

15 (14.5)

40–60

26 (50.0)

26 (51.0)

52 (50.5)

> 60

17 (32.7)

19 (37.3)

36 (35.0)

Age-median (IQR)

54 (46–62)

57 (47–64)

56 (46–63)

Gender

Female

31 (59.6)

30 (58.8)

61 (59.2)

Male

21 (40.4)

21 (41.2)

42 (40.8)

HIV status

Positive

6 (11.5)

15 (28.8)

21 (18.5)

On ART

5 (83.3)

11 (73.3)

16 (76.2)

Not on ART

1 (16.7)

4 (26.7)

5 (24.8)

Negative

37 (71.2)

26 (51.0)

63 (62.1)

Unknown

9 (17.3)

10 (19.6)

19 (19.4)

Smoking

Current smoker

5 (9.6)

6 (11.8)

11 (10.7)

Ex-smoker

11 (21.2)

11 (21.6)

22 (21.7)

BMI

BMI ≥ 30 kg/m2

29 (55.8)

27 (52.9)

56 (54.4)

BMI-Median (IQR)

31.2 (26.8–37.6)

31.0 (26.8–36.0)

SARS-CoV-2 clade on sequencing

34

32

66

19A

2 (5.9)

2 (6.3)

4 (6.1)

20A

4 (11.8)

6 (18.8)

10 (15.2)

20B

5 (14.7)

2 (6.3)

7 (10.6)

20H/501Y.V2

23 (67.6)

22 (68.8)

45 (68.2)

Back to article page